Still hidden behind a screen

D. Burgess

DOI: https://doi.org/10.1038/nrc3101

2011-06-24

Abstract:

What problem does this paper attempt to address?

Prussian Blue Nanozyme Normalizes Microenvironment to Delay Osteoporosis

Chenyi Ye,Wei Zhang,Yongzheng Zhao,Kai Zhang,Weiduo Hou,Mo Chen,Jinwei Lu,Jianrong Wu,Rongxin He,Wei Gao,Yuanyi Zheng,Xiaojun Cai

DOI: https://doi.org/10.1002/adhm.202200787

2022-01-01

Abstract:Osteoporosis (OP) is the most common orthopedic disease in the elderly and the main cause of age-related mortality and disability. However, no satisfactory intervention is currently available in clinical practice. Thus, an effective therapy to prevent or delay the development of OP should be devised. Osteoclastogenesis overactivation and excessive bone resorption are the main characteristics of OP. Accordingly, a paradigm for nanozyme-mediated normalization of the disease microenvironment to regulate osteoclast differentiation and delay OP is proposed. Hollow Prussian blue nanozymes (HPBZs) are prepared via template-free hydrothermal synthesis and selected as representative nanozymes. The intrinsic osteoclast activity-remodeling bioactivities of the HPBZs are explored in vitro and in vivo, focusing on their impact on osteogenesis and specific molecular mechanisms using an OP murine model. The HPBZs significantly normalize the OP microenvironment, thereby inhibiting osteoclast formation and osteoclast resorption, possibly owing to the suppression of intracellular reactive oxygen species generation, the mitogen-activated protein kinase, and nuclear factor kappa B signaling pathways. Consistently, in an ovariectomy-induced OP murine model, HPBZ treatment significantly attenuates osteoporotic bone loss in vivo. The findings confirm the HPBZ-mediated normalization of the disease microenvironment for the treatment of OP and suggest its application to other inflammation-related diseases.
Bone‐Targeting and Multishelled Oral Eldecalcitol Nanoparticles Improve Osteoporosis by Reconstruction of Osteogenic‐Osteoclastic Homeostasis

Lingxiao Meng,Wanli Ma,Yuping Jiang,Xiaozhuang Li,Minglei Zhang,Rundong Yuan,Yaqiu Fu,Haohua Ma,Xiong Lu,Lu Han,Hongrui Liu,Minqi Li

DOI: https://doi.org/10.1002/adfm.202404549

IF: 19

2024-05-25

Advanced Functional Materials

Abstract:The step‐wise eldecalcitol delivery nanoparticles (ME‐ED‐71@PCA) with bone‐targeting ability, gastrointestinal protection, and good intestinal penetration properties is established to improve postmenopausal osteoporosis (PMOP). The ME‐ED‐71@PCA exerted superior therapeutic efficacy in re‐establishing osteogenic‐osteoclastic homeostasis in PMOP mice by promoting osteogenic differentiation of bone marrow mesenchymal stem cells as well as inhibiting the osteoclast differentiation, without side effects. Current treatment of postmenopausal osteoporosis (PMOP) focuses on systemic administration of medication, neglecting to proactively modulate the local microenvironment of skeletal system for superior therapeutic performance. Eldecalcitol (ED‐71), a novel drug for treating osteoporosis, still requires research to overcome high‐frequency delivery and low‐utilization. Here, a bone‐targeting and multishelled nanoparticles are developed for step‐wise release of ED‐71. The nanoparticles are achieved by using the chitosan/alginate outer layer as protective barrier against gastric acid, pectin middle layer as adhesive agent that improved intestinal penetration, and ethylene diamine tetraacetic acid‐grafted mesoporous silica nanomaterials core as bone‐targeting nanocarriers. After oral administration, the ED‐71‐loaded nanoparticles (ME‐ED‐71@PCA) promotes osteogenic differentiation of bone marrow mesenchymal stem cells by reducing intracellular oxidative stress, and inhibits the osteoclast differentiation. ME‐ED‐71@PCA improves bone mass in ovariectomized‐mice by promoting osteogenesis and inhibiting osteoclastogenesis, and the efficacy is more pronounced than ED‐71 alone. ME‐ED‐71@PCA exhibits satisfactory therapeutic performance due to its step‐wise drug release and bone‐targeting compared to ED‐71 administration, providing a new approach to re‐establish bone metabolic homeostasis in PMOP.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
A Bone Targeting Nanoparticle Loaded Ogp to Restore Bone Homeostasis for Osteoporosis Therapy

Shiqing Ma,Shendan Xu,Minting Li,Yaqi Du,Guangjie Tian,Jiayin Deng,Wenyi Zhang,Pengfei Wei,Bo Zhao,Xuesong Zhang,Zihao Liu,Yonglan Wang

DOI: https://doi.org/10.1002/adhm.202300560

IF: 10

2023-08-12

Advanced Healthcare Materials

Abstract:Restoring bone homeostasis is the key to the treatment of osteoporosis. How to increase osteogenic ability or inhibit osteoclast activity has always been a topic of great concern. In recent years, short peptides with biological activity have received great attention in bone repair. However, the application of short peptides is still limited due to the lack of a stable and targeted delivery system. We designed poly(lactic‐co‐glycolic acid) (PLGA) nanoparticles modified by alendronate (AL) to transport osteogenic peptides (OGP) (AL‐PLGA@P NPs). Benefiting from the high affinity of AL for hydroxyapatite, AL‐PLGA@P NPs have the ability to target bone. In this delivery system, OGP that promotes osteogenesis synergizes with AL, which inhibits osteoclasts, to regulate bone homeostasis, which gives them more advantages in the treatment of osteoporosis. Our data showed that nanoparticles could selectively deliver peptides to the bone surface without systemic toxicity. Moreover, nanoparticles could upregulate osteogenesis‐related factors (ALP, Runx‐2, BMP2) and downregulate osteoclast‐related factors (TRAP, CTSK) in vitro. With AL‐PLGA@P NPs, bone microarchitecture and bone mass were improved in ovariectomized osteoporosis rats. Therefore, this study proposes a novel osteoporosis‐based drug system that effectively improves bone density. This article is protected by copyright. All rights reserved

nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials
Bone-targeting cell membrane-engineered CaCO 3 -based nanoparticles restore local bone homeostasis for microenvironment-responsive osteoporosis treatment

Yan Huang,Maowen Chen,Yiding Shen,Xinkun Shen,Menghuan Li,Yanan Li,Yuan Liu,Kaiyong Cai,Zhong Luo,Yan Hu

DOI: https://doi.org/10.1016/j.cej.2023.144145

IF: 15.1

2023-06-23

Chemical Engineering Journal

Abstract:Osteoporosis is a common bone disease characterized by the systemic disruption of hone homeostasis, where the imbalance between bone resorption and formation causes deterioration of bone structure and bone mass loss. Targeted restoration of bone hemostasis has thus become a promising strategy for osteoporosis treatment. For this purpose, we report a bone-targeted nanoformulation based on CaCO 3 nanomaterials, which could be activated in the acidic osteoporotic microenvironment and cooperatively regulate the activity of osteoclasts and osteoblasts to reverse bone deterioration. Herein, a clinical antiosteoporosis drug β-estradiol (E2) is first biomineralized using CaCO 3 to form physiologically stable nanocores. Meanwhile, azido groups are introduced onto MC3T3-E1 cells through incubation with AC 4 ManNAz. The azido-tagged MC3T3-E1 cell membranes are extracted for the camouflaging of the CaCO 3 @E2 nanocores to enhance their in vivo stability and availability, while also enabling the surface modification of bone-targeting dibenzocyclooctyne-tagged alendronate moieties via copper-free click reaction. After the selective deposition into acidic osteoporotic bone tissues, the CaCO 3 @E2 cores would be spontaneously degraded to release E2 and Ca 2+ ions, which would systematically inhibit the activity of osteoclasts while promoting osteoblast-mediated new bone formation, eventually ameliorating the osteoporosis symptoms. This study offers an effective approach for osteoporosis treatment in the clinics.

engineering, chemical, environmental
Reversing the Imbalance in Bone Homeostasis Via Sustained Release of SIRT-1 Agonist to Promote Bone Healing under Osteoporotic Condition

Wei Zhang,Xingzhi Zhou,Weiduo Hou,Erman Chen,Chenyi Ye,Mo Chen,Qian Lu,Xiaohua Yu,Weixu Li

DOI: https://doi.org/10.1016/j.bioactmat.2022.04.017

IF: 18.9

2023-01-01

Bioactive Materials

Abstract:The imbalance of bone homeostasis is the root cause of osteoporosis. However current therapeutic approaches mainly focus on either anabolic or catabolic pathways, which often fail to turn the imbalanced bone metabolism around. Herein we reported that a SIRT-1 agonist mediated molecular therapeutic strategy to reverse the imbalance in bone homeostasis by simultaneously regulating osteogenesis and osteoclastogenesis via locally sustained release of SRT2104 from mineral coated acellular matrix microparticles. Immobilization of SRT2104 on mineral coating (MAM/SRT) harnessing their electrostatic interactions resulted in sustained release of SIRT-1 agonist for over 30 days. MAM/SRT not only enhanced osteogenic differentiation and mineralization, but also attenuated the formation and function of excessive osteoclasts via integrating multiple vital upstream signals (β-catenin, FoxOs, Runx2, NFATc1, etc.) in vitro. Osteoporosis animal model also validated that it accelerated osteoporotic bone healing and improved osseointegration of the surrounding bone. Overall, our work proposes a promising strategy to treat osteoporotic bone defects by reversing the imbalance in bone homeostasis using designated small molecule drug delivery systems.
Inflammatory microenvironment regulation and osteogenesis promotion by bone-targeting calcium and magnesium repletion nanoplatform for osteoporosis therapy

Zhenzhen Weng,Jing Ye,Changxiong Cai,Zikang Liu,Yuanyuan Liu,Yingying Xu,Jinghong Yuan,Wei Zhang,Lubing Liu,Junkai Jiang,Xigao Cheng,Xiaolei Wang

DOI: https://doi.org/10.1186/s12951-024-02581-7

IF: 10.2

2024-06-07

Journal of Nanobiotechnology

Abstract:Osteoporosis is the most common bone metabolic disease that affects the health of middle-aged and elderly people, which is hallmarked by imbalanced bone remodeling and a deteriorating immune microenvironment. Magnesium and calcium are pivotal matrix components that participate in the bone formation process, especially in the immune microenvironment regulation and bone remodeling stages. Nevertheless, how to potently deliver magnesium and calcium to bone tissue remains a challenge. Here, we have constructed a multifunctional nanoplatform composed of calcium-based upconversion nanoparticles and magnesium organic frameworks (CM-NH 2 -PAA-Ald, denoted as CMPA), which features bone-targeting and pH-responsive properties, effectively regulating the inflammatory microenvironment and promoting the coordination of osteogenic functions for treating osteoporosis. The nanoplatform can efficaciously target bone tissue and gradually degrade in response to the acidic microenvironment of osteoporosis to release magnesium and calcium ions. This study validates that CMPA possessing favorable biocompatibility can suppress inflammation and facilitate osteogenesis to treat osteoporosis. Importantly, high-throughput sequencing results demonstrate that the nanoplatform exerts a good inflammatory regulation effect through inhibition of the nuclear factor kappa-B signaling pathway, thereby normalizing the osteoporotic microenvironment. This collaborative therapeutic strategy that focuses on improving bone microenvironment and promoting osteogenesis provides new insight for the treatment of metabolic diseases such as osteoporosis.

biotechnology & applied microbiology,nanoscience & nanotechnology
Nanoengineering multifunctional extracellular vesicles availably mitigate bone loss in osteoporosis through binding to RANKL and rebalancing the Treg/Th17 cells

Zhengyu Yang,Zhen Yang,Lin Ding,Cong Liu,Fujian Zhao,Xiaofeng Chen,Chang Du

DOI: https://doi.org/10.1016/j.cej.2023.143391

IF: 15.1

2023-05-17

Chemical Engineering Journal

Abstract:The balance between regulatory T cells (Treg) and T helper 17 cells (Th17) plays an important role in bone loss in osteoporosis. Hyperactivation of Th17 cells, where a large amount of cytokine RANKL is secreted, promotes the osteoclast phenotype. The restoration of immune homeostasis of Treg/Th17 cells could inhibit bone loss. However, the engineered strategy is still absent. Herein, we report an immunomodulatory bioactive glass nanoparticle-engineered bone marrow-derived macrophages (BMDMs) to generate extracellular vesicles (SrBGN + Mφ-EVs), which could regulate the Treg/Th17 balance and inhibit the bone loss in osteoporosis. SrBGN + Mφ-EVs contain both SrBGNs immunomodulatory active ions and anti-inflammatory factors of M2-type BMDMs and have good biocompatibility in vitro . SrBGN + Mφ-EVs regulated the Treg/Th17 balance by promoting Treg cell differentiation and inhibiting Th17 cell differentiation in vitro . More importantly, more RANK was enriched on the surface of SrBGN + Mφ-EVs with strong affinity to RANKL, which acted as a competitive inhibitor of RANKL-RANK interaction and inhibited the activation of osteoclasts. In vivo experiments, SrBGN + Mφ-EVs showed excellent biocompatibility and improved the immune environment of osteoporotic mice to inhibit bone loss. This study may provide new ideas for the regulatory strategy of bioactive glass and its engineered extracellular vesicles in re-establishing immune homeostasis in osteoporosis, as well as a solution for treating bone resorption disorders.

engineering, chemical, environmental
Colon-targeted Engineered Postbiotics Nanoparticles Alleviating Osteoporosis through Gut-Bone Axis

Guangjun Nie,Tingting Yu,Rushui Bai,Zeming Wang,Yuting Qin,Jingwei Wang,Yaohua Wei,Ruifang Zhao,Bing Han

DOI: https://doi.org/10.21203/rs.3.rs-4233502/v1

2024-01-01

Abstract:Abstract The potential for mitigating intestinal inflammation through the gut-bone axis in the treatment of osteoporosis is significant. While various gut-derived postbiotics or bacterial metabolites have been created as dietary supplements to prevent or reverse bone loss, their efficacy and safety still need improvement. Herein, a colon-targeted drug delivery system was developed using surface engineering of polyvinyl butyrate nanoparticles by shellac resin to achieve sustained release of postbiotics butyric acid at the colorectal site. These engineered postbiotics nanoparticles can effectively suppress macrophage inflammatory activation, modulate the redox balance, and regulate the composition of the gut microbiota, thereby restoring epithelial barriers, inhibiting bacterial invasion, and down-regulating pro-inflammatory responses. As a result, the remission of systemic inflammation is accompanied by a rebalancing of osteoblast and osteoclast activity, alleviating IBD-related and post-menopausal bone loss. This study provides valuable insights into the gut-bone axis and establishes a promising and safe therapeutic strategy for osteoporosis.
Osteophilic and Dual‐Regulated Alendronate‐Gene Lipoplexes for Reversing Bone Loss

Junjie Li,Ruizhi Zhang,Yawei Du,Gongwen Liu,Yu Dong,Miao Zheng,Wenguo Cui,Peng Jia,Youjia Xu

DOI: https://doi.org/10.1002/smll.202303456

IF: 13.3

2023-07-13

Small

Abstract:The osteophilic and dual‐regulated alendronate‐gene lipoplexes are formulated via a thin‐film dispersion method and electrostatic interaction. The physical barriers are generated by alendronate on the lipoplexes surface, and the genetic signals are produced by antagomir inside the lipoplexes. More notably, alendronate and antagomir‐378a‐3p synergistically regulate osteoclastogenesis and bone resorption through a dual‐driven mechanism, thereby dramatically reversing bone loss. The pathogenesis of postmenopausal osteoporosis (PMOP) is mainly determined by the adhesion of osteoclasts to the bone matrix and the involvement of various molecules in bone resorption. The dual regulation strategy of the physical barriers of bone matrix and intracellular gene regulation generated by advanced biomaterials is a decent alternative for the treatment of PMOP. Herein, for the first time, it is identified that hsa‐miR‐378i/mmu‐miR‐378a‐3p are closely associated with PMOP. Then, an osteophilic and dual‐regulated alendronate‐gene lipoplex (antagomir@Aln‐Lipo), composed of medicative alendronate‐functionalized liposomal vehicle and encapsulated specific microRNAs is engineered, for bone‐targeting delivery of genes to achieve combined mitigation of bone loss. Alendronate targets hydroxyapatite in the bone matrix and occupies the adhesion site of osteoclasts, thus providing the "physical barriers". Antagomir is coupled precisely to specific endogenous microRNAs, thus providing the "genetic signals". These functionalized lipoplexes exhibited long‐term stability and good transfection efficiency. It is proven that antagomir@Aln‐Lipo could synergistically regulate osteoclastogenesis and bone resorption in vitro and in vivo. Furthermore, intravenous injection of antagomir@Aln‐Lipo efficiently reverses bone loss through a dual mechanism driven by alendronate and antagomir‐378a‐3p. In conclusion, the osteophilic and dual‐regulated antagomir@Aln‐Lipo offers a brand‐new bifunctional strategy for the precise treatment of PMOP.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
Nanoparticles functionalized with stem cell secretome and CXCR4-overexpressing endothelial membrane for targeted osteoporosis therapy

Chi Zhang,Wei Zhang,Dashuai Zhu,Zhenhua Li,Zhenzhen Wang,Junlang Li,Xuan Mei,Wei Xu,Ke Cheng,Biao Zhong

DOI: https://doi.org/10.1186/s12951-021-01231-6

IF: 10.2

2022-01-15

Journal of Nanobiotechnology

Abstract:Abstract Background Osteoporosis is a chronic condition affecting patients’ morbidity and mortality and represents a big socioeconomic burden. Because stem cells can proliferate and differentiate into bone-forming cells, stem cell therapy for osteoporosis has been widely studied. However, cells as a live drug face multiple challenges because of their instability during preservation and transportation. In addition, cell therapy has potential adverse effects such as embolism, tumorigenicity, and immunogenicity. Results Herein, we sought to use cell-mimicking and targeted therapeutic nanoparticles to replace stem cells. We fabricated nanoparticles (NPs) using polylactic-co-glycolic acid (PLGA) loaded with the secretome (Sec) from mesenchymal stem cells (MSCs) to form MSC-Sec NPs. Furthermore, we cloaked the nanoparticles with the membranes from C–X–C chemokine receptor type 4 (CXCR4)-expressing human microvascular endothelial cells (HMECs) to generate MSC-Sec/CXCR4 NP. CXCR4 can target the nanoparticles to the bone microenvironment under osteoporosis based on the CXCR4/SDF-1 axis. Conclusions In a rat model of osteoporosis, MSC-Sec/CXCR4 NP were found to accumulate in bone, and such treatment inhibited osteoclast differentiation while promoting osteogenic proliferation. In addition, our results showed that MSC-Sec/CXCR4 NPs reduce OVX-induced bone mass attenuation in OVX rats. Graphical Abstract

biotechnology & applied microbiology,nanoscience & nanotechnology
Synthetic biology‐based bacterial extracellular vesicles displaying BMP‐2 and CXCR4 to ameliorate osteoporosis

Han Liu,Peiran Song,Hao Zhang,Fengjin Zhou,Ning Ji,Mingkai Wang,Guangyin Zhou,Ruina Han,Xinru Liu,Weizong Weng,Haoqi Tan,Sicheng Wang,Lei Zheng,Yingying Jing,Jiacan Su

DOI: https://doi.org/10.1002/jev2.12429

2024-04-06

Journal of Extracellular Vesicles

Abstract:Osteoporosis (OP) is a systematic bone disease characterized by low bone mass and fragile bone microarchitecture. Conventional treatment for OP has limited efficacy and long‐term toxicity. Synthetic biology makes bacterial extracellular vesicle (BEVs)‐based therapeutic strategies a promising alternative for the treatment of OP. Here, we constructed a recombinant probiotics Escherichia coli Nissle 1917‐pET28a‐ClyA‐BMP‐2‐CXCR4 (ECN‐pClyA‐BMP‐2‐CXCR4), in which BMP‐2 and CXCR4 were overexpressed in fusion with BEVs surface protein ClyA. Subsequently, we isolated engineered BEVs‐BMP‐2‐CXCR4 (BEVs‐BC) for OP therapy. The engineered BEVs‐BC exhibited great bone targeting in vivo. In addition, BEVs‐BC had good biocompatibility and remarkable ability to promote osteogenic differentiation of BMSCs. Finally, the synthetic biology‐based BEVs‐BC significantly prevented the OP in an ovariectomized (OVX) mouse model. In conclusion, we constructed BEVs‐BC with both bone‐targeting and bone‐forming in one‐step using synthetic biology, which provides an effective strategy for OP and has great potential for industrialization.

cell biology
Pueraria lobata-derived exosome-like nanovesicles alleviate osteoporosis by enhacning autophagy

Weiqiang Zhan,Mingzhu Deng,Xinqia Huang,Dong Xie,Xiang Gao,Jiaxian Chen,Zhen Shi,Jiaxu Lu,Hao Lin,Peng Li

DOI: https://doi.org/10.1016/j.jconrel.2023.11.020

Abstract:Osteoporosis (OP) is the most common bone disorder worldwide, especially in postmenopausal women. However, many OP drugs are not suitable for long term use due to major adverse effects. Therefore, there is an urgent need to identify more effective and safe therapeutic drugs. Pueraria lobata has been reported to promote osteoblast growth in bone regeneration, but the exact mechanisms still need further exploration. The current study found that Pueraria lobata-derived exosome-like nanovesicles (PELNs) promoting primary human bone mesenchymal stem cells (hBMSCs) differentiation and mineralization both in vitro and in ovariectomized (OVX)-induced osteoporotic rats. Interestingly, the relative abundance of harmful strains significantly decreased in the intestine of the osteoporosis SD rat model administrated PELNs via the regulation of trimethylamine-N-oxide (TMAO), a metabolite of gut microbiota. Moreover, RNA sequencing revealed that the osteogenic activity of PELNs is revealed to autophagy signaling. In vitro and in vivo experiments also showed that the treatment with PELNs promoted the differentiation and function of hBMSCs by elevating autophagy via the degradation of TMAO. Collectively, PELNs demonstrate promise as a therapeutic approach for OP, with TMAO emerging as a potential target of OP treatment.
Alendronate Functionalized Bone-Targeting Pomolic Acid Liposomes Restore Bone Homeostasis for Osteoporosis Treatment

Demeng Xia,Qingqing Qian,Sheng Wang,Xiao Dong,Ying Liu

DOI: https://doi.org/10.2147/IJN.S462514

2024-08-06

Abstract:Introduction: Osteoporosis, characterized by dysregulation of osteoclastic bone resorption and osteoblastic bone formation, severely threatens human health during aging. However, there is still no good therapy for osteoporosis, so this direction requires our continuous attention, and there is an urgent need for new drugs to solve this problem. Methods: Traditional Chinese Medicine Salvia divinorum monomer pomolic acid (PA) could effectively inhibit osteoclastogenesis and ovariectomized osteoporosis. However, its poor solubility and lack of targeting severely limits its further application. A novel bone-targeting nanomedicine (PA@TLipo) has been developed to reconstruct the osteoporotic microenvironment by encapsulating pomolic acid in alendronate-functionalized liposomes. Through a series of operations such as synthesis, purification, encapsulation, and labeling, the PA@TLipo have been prepared. Moreover, the cytotoxicity, bone targeting and anti-osteoporosis effect was verified by cell and animal experiments. Results: In the aspect of targeting, the PA@TLipo can effectively aggregate on the bone tissue to reduce bone loss, and in terms of toxicity, PA@TLipo could increase the bone target ability in comparison to nontargeted liposome, thereby mitigating systemic cytotoxicity. Moreover, PA@TLipo inhibited osteoclast formation and bone resorption in vitro and reduced bone loss in ovariectomy-induced osteoporotic mice. Conclusion: In this study, a novel therapeutic agent was designed and constructed to treat osteoporosis, consisting of a liposome material as the drug pocket, PA as the anti-osteoporosis drug, and ALN as the bone-targeting molecule. And our study is the first to employ a bone-targeted delivery system to deliver PA for OVX-induced bone loss, providing an innovative solution for treating osteoporosis.
Injectable double-crosslinked bone cement with enhanced bone adhesion and improved osteoporotic pathophysiological microenvironment for osteoregeneration in osteoporosis

Lingfei Zhao,Chenyu Liu,Xing Chen,Zirui He,Shuiquan Zhang,Anan Zhang,Shuaimin Tang,Zihan Wu,Changsheng Liu,Yuan Yuan

DOI: https://doi.org/10.1016/j.bioactmat.2024.09.032

2024-10-02

Abstract:The osteoporotic bone defect caused by excessive activity of osteoclasts has posed a challenge for public healthcare. However, most existing bioinert bone cement fails to effectively regulate the pathological bone microenvironment and reconstruct bone homeostasis in the presence of osteoclast overactivity and osteoblast suppression. Herein, inspired by natural bone tissue, an in-situ modulation system for osteoporotic bone regeneration is developed by fabricating an injectable double-crosslinked PEGylated poly(glycerol sebacate) (PEGS)/calcium phosphate cement (CPC) loaded with sodium alendronate (ALN) (PEGS/CPC@ALN) adhesive bone cement. By incorporating ALN, the organic-inorganic interconnection within PEGS/CPC@ALN results in a 100 % increase in compression modulus and energy dissipation efficiency. Additionally, PEGS/CPC@ALN effectively adheres to the bone by bonding with amine and calcium ions present on the bone surface. Moreover, this in-situ regulation system comprehensively mitigates excessive bone resorption through the buffering effect of CPC to improve the acidic microenvironment of osteoporotic bone and the release of ALN to inhibit hyperactive osteoclasts, and facilitates stem cell proliferation and differentiation into osteoblasts through calcium ion release. Overall, the PEGS/CPC@ALN effectively regulates the pathological microenvironment of osteoporosis while promoting bone regeneration through synergistic effects of drugs and materials, thereby improving bone homeostasis and enabling minimally invasive treatment for osteoporotic defects.
Bone targeting antioxidative nano-iron oxide for treating postmenopausal osteoporosis

Liming Zheng,Zaikai Zhuang,Yixuan Li,Tianshu Shi,Kai Fu,Wenjin Yan,Lei Zhang,Peng Wang,Lan Li,Qing Jiang

DOI: https://doi.org/10.1016/j.bioactmat.2021.11.012

IF: 18.9

2022-08-01

Bioactive Materials

Abstract:Osteoporosis is the most common degenerative orthopedic disease in the elderly. Recently, the therapeutic methods for osteoporosis have shifted towards the regulation of local immunity in bone tissues, which could provide a suitable environment for the positive regulation of bone metabolism, promoting osteogenic differentiation and inhibiting osteoclast differentiation. Our previous work demonstrated that iron oxide nanoparticles (IONPs) could positively regulate bone metabolism <i>in vitro</i>. In this study, we further demonstrated that daily administration of IONPs relieved estrogen deficiency-induced osteoporosis via scavenging reactive oxygen species <i>in vivo.</i> Meanwhile, IONPs promoted the osteogenic differentiation of bone marrow mesenchymal stem cells and inhibited the osteoclast differentiation of monocytes from IONPs treated mice. Besides, alendronate, a clinically used anti-osteoporosis bisphosphate, was employed to precisely deliver the IONPs to the bone tissues and played a synergically therapeutic role. Eventually, we verified the bone targeting ability, therapeutic efficiency, and biocompatibility of the novel bone target iron oxides in ovariectomy-induced osteoporotic mice. By applying BTNPs, the OVX-induced osteoporosis was significantly revised in mice models via the positive regulation of bone metabolism.

engineering, biomedical,materials science, biomaterials
Radial Extracorporeal Shock Wave Responsive Precise Nanoplatform for Effective Osteoporosis Sequential Treatment

Wei Liang,Kui Chen,Linwen Lv,Yujiao Wang,Jianglong Kong,Haojun Liang,Haochong Zhang,Jiaxin Zhang,Ziteng Chen,Ya-nan Chang,Juan Li,Gengyan Xing,Gengmei Xing

DOI: https://doi.org/10.1016/j.cej.2021.130687

IF: 15.1

2021-01-01

Chemical Engineering Journal

Abstract:Osteoporosis (OP), which is associated with an imbalance between osteoblasts (OBs) and osteoclasts (OCs), is sequentially treated with anabolic and anti-resorption agents in the clinic to improve outcome. However, the long duration of treatment and the accuracy of dosing are still major limiting factors affecting outcome. In the present study, a radial extracorporeal shock wave (rESW) responsive precise sequential release nanoplatform with zoledronic acid (ZOL) adsorbed onto the surface of hollow hydroxyapatite nanoparticles (hNPs) is reported. The ZOL on the surface of hNPs was rapidly released and inhibited hyperactivation of OCs in the OP region. The remaining hNPs with a wall thickness of approximately 10 nm were crushed into fragments by rESW to control Ca2+ release and proton neutralization, promoting anabolic metabolism. In addition, mechanical stimulation by rESW helped bone formation. In vivo, maximum anti-resorption and pro-anabolic effects, marked improvements in bone-associated parameters and mechanical properties in ovariectomy-induced OP rats were achieved following co-treatment with rESW and ZOL-hNPs. These findings suggest that this precise sequential release nanoplatform based on rESW can be used for effective anti-OP treatment.
Structure-based Development of an Osteoprotegerin-Like Glycopeptide That Blocks RANKL/RANK Interactions and Reduces Ovariectomy-Induced Bone Loss in Mice.

Chao Liu,Xiao Chen,Xin Zhi,Weizong Weng,Quan Li,Xiang Li,Yan Zou,Jiacan Su,Hong-Gang Hu

DOI: https://doi.org/10.1016/j.ejmech.2018.01.022

IF: 7.088

2018-01-01

European Journal of Medicinal Chemistry

Abstract:Osteoporosis is a metabolic bone disease characterized by low bone mass and micro-architectural deterioration of bone, for which the underlying mechanism is an imbalance between bone resorption and bone remodeling. The protein-protein interactions between receptor activator of nuclear factor-κB ligand (RANKL), RANK (its receptor), and osteoprotegerin (OPG), are known to mediate the development and activation of osteoclasts in bone remodeling, and are regarded as a pivotal therapeutic target for the treatment of osteoporosis. Herein, we disclose the successful development of a novel glycopeptide (OM-2), the structure of which is based on the key interacting sites of the reported RANKL and OPG crystal structure. OM-2 exhibited potent binding affinity with RANKL and resistance to degradation by protease enzymes. It also blocked RANKL/RANK interactions, and inhibited osteoclastogenesis in vitro. In vivo studies confirmed that OM-2 could effectively reduce bone loss and inhibit osteoclast activation in ovariectomized (OVX) mice at a dosage of 20.0 mg/kg/day. Accordingly, OM-2 is suggested as a therapeutic candidate for postmenopausal osteoporosis (PMOP) and osteoclastogenesis-related diseases like rheumatoid arthritis (RA). More importantly, its identification validates our structure-based strategy for the development of drugs that target the RANKL/RANK/OPG system.
The nanoformula of zoledronic acid and calcium carbonate targets osteoclasts and reverses osteoporosis

Fei Jia,Lifo Ruan,Chuanchao Du,Yu Liu,Xiaomeng Cai,Rui Dou,Jiayu Zhang,Xiaoguang Liu,Jun Chen,Xingcai Zhang,Zhifang Chai,Yi Hu

DOI: https://doi.org/10.1016/j.biomaterials.2023.122059

IF: 14

2023-02-18

Biomaterials

Abstract:Osteoporosis is known as an imbalance in bone catabolism and anabolism. Overactive bone resorption causes bone mass loss and increased incidence of fragility fractures. Antiresorptive drugs are widely used for osteoporosis treatment, and their inhibitory effects on osteoclasts (OCs) have been well established. However, due to the lack of selectivity, their off-target and side effects often bring suffering to patients. Herein, an OCs' microenvironment-responsive nanoplatform HA-MC/CaCO 3 / (HMCZP) is developed, consisting of succinic anhydride (SA)-modified poly(β-amino ester) (PBAE) micelle, calcium carbonate shell, minocycline-modified hyaluronic acid (HA-MC) and zoledronic acid (ZOL). Results indicate that HMCZP, as compared with the first-line therapy, could more effectively inhibit the activity of mature OCs and significantly reverse the systemic bone mass loss in ovariectomized mice. In addition, the OCs-targeted capacity of HMCZP makes it therapeutically efficient at sites of severe bone loss and allows it to reduce the adverse effects of ZOL, such as acute phase reaction. High-throughput RNA sequencing (RNA-seq) reveals that HMCZP could down-regulate a critical osteoporotic target, tartrate-resistant acid phosphatase (TRAP), as well as other potential therapeutical targets for osteoporosis. These results suggest that an intelligent nanoplatform targeting OCs is a promising strategy for osteoporosis therapy.

engineering, biomedical,materials science, biomaterials
Citric acid-modified pH-sensitive bone-targeted delivery of estrogen for the treatment of postmenopausal osteoporosis

Zhong-Hua Chen,De-Yan Du,Yi-Fei Fu,Jun-Jie Wu,Dan-Yang Guo,Yue-Yue Li,Meng-Nan Chen,Zheng-Dong Yuan,Kai-Wen Zhang,Zhen-Yu Zhang,Xia Li,Feng-Lai Yuan

DOI: https://doi.org/10.1016/j.mtbio.2023.100747

IF: 8.2

2023-07-28

Materials Today Bio

Abstract:Bone targeted delivery of estrogen offers great promise for the clinical application of estrogen in the treatment of postmenopausal osteoporosis (PMOP). However, the current bone-targeted drug delivery system still has several issues that need to be solved, such as the side effects of bone-targeted modifier molecules and the failure of the delivery system to release rapidly in the bone tissue. It is important to aggressively search for new bone-targeted modifier molecules and bone microenvironment-responsive delivery vehicles. Inspired by the distribution of citric acid (CA) mainly in bone tissue and the acidic bone resorption microenvironment, we constructed a CA-modified diblock copolymer poly(2-ethyl-2-oxazoline)–poly(ε-caprolactone) (CA-PEOz) drug delivery system. In our study, we found that the CA modification significantly increased the bone targeting of this drug delivery system, and the delivery system was able to achieve rapid drug release under bone acidic conditions. The delivery system significantly reduced bone loss in postmenopausal osteoporotic mice with a significant reduction in estrogenic side effects on the uterus. In summary, our study shows that CA can act as an effective bone targeting modifier molecule and provides a new option for bone targeting modifications. Our study also provides a new approach for bone-targeted delivery of estrogen for the treatment of PMOP.

engineering, biomedical,materials science, biomaterials
Regulating Type H Vessel Formation and Bone Metabolism via Bone‐Targeting Oral Micro/Nano‐Hydrogel Microspheres to Prevent Bone Loss

Junjie Li,Gang Wei,Gongwen Liu,Yawei Du,Ruizhi Zhang,Aifei Wang,Baoshan Liu,Wenguo Cui,Peng Jia,Youjia Xu

DOI: https://doi.org/10.1002/advs.202207381

IF: 15.1

2023-03-28

Advanced Science

Abstract:In this study, the author construct a pH‐responsive shell‐core structured micro/nano‐hydrogel microspheres (PDAP@Alg/Cs) using gas microfluidics and ionic cross‐linking technique. The PDAP@Alg/Cs can achieve oral delivery, intragastric protection, intestinal slow/controlled release, and active targeting to bone tissue. In conclusion, this novel oral PDAP@Alg/Cs can simultaneously accelerate intraosseous vascularization and decrease bone resorption, offering a brand‐new approach to prevent postmenopausal osteoporosis. Postmenopausal osteoporosis is one of the most prevalent skeletal disorders in women and is featured by the imbalance between intraosseous vascularization and bone metabolism. In this study, a pH‐responsive shell–core structured micro/nano‐hydrogel microspheres loaded with polyhedral oligomeric silsesquioxane (POSS) using gas microfluidics and ionic cross‐linking technology are developed. This micro/nano‐hydrogel microsphere system (PDAP@Alg/Cs) can achieve oral delivery, intragastric protection, intestinal slow/controlled release, active targeting to bone tissue, and thus negatively affecting intraosseous angiogenesis and osteoclastogenesis. According to biodistribution data, PDAP@Alg/Cs can successfully enhance drug intestinal absorption and bioavailability through intestine adhesion and bone targeting after oral administration. In vitro and in vivo experiments reveal that PDAP@Alg/Cs promoted type H vessel formation and inhibited bone resorption, effectively mitigating bone loss by activating HIF‐1α/VEGF signaling pathway and promoting heme oxygenase‐1 (HO‐1) expression. In conclusion, this novel oral micro/nano‐hydrogel microsphere system can simultaneously accelerate intraosseous vascularization and decrease bone resorption, offering a brand‐new approach to prevent postmenopausal osteoporosis.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry

Still hidden behind a screen

Prussian Blue Nanozyme Normalizes Microenvironment to Delay Osteoporosis

Bone‐Targeting and Multishelled Oral Eldecalcitol Nanoparticles Improve Osteoporosis by Reconstruction of Osteogenic‐Osteoclastic Homeostasis

A Bone Targeting Nanoparticle Loaded Ogp to Restore Bone Homeostasis for Osteoporosis Therapy

Bone-targeting cell membrane-engineered CaCO 3 -based nanoparticles restore local bone homeostasis for microenvironment-responsive osteoporosis treatment

Reversing the Imbalance in Bone Homeostasis Via Sustained Release of SIRT-1 Agonist to Promote Bone Healing under Osteoporotic Condition

Inflammatory microenvironment regulation and osteogenesis promotion by bone-targeting calcium and magnesium repletion nanoplatform for osteoporosis therapy

Nanoengineering multifunctional extracellular vesicles availably mitigate bone loss in osteoporosis through binding to RANKL and rebalancing the Treg/Th17 cells

Colon-targeted Engineered Postbiotics Nanoparticles Alleviating Osteoporosis through Gut-Bone Axis

Osteophilic and Dual‐Regulated Alendronate‐Gene Lipoplexes for Reversing Bone Loss

Nanoparticles functionalized with stem cell secretome and CXCR4-overexpressing endothelial membrane for targeted osteoporosis therapy

Synthetic biology‐based bacterial extracellular vesicles displaying BMP‐2 and CXCR4 to ameliorate osteoporosis

Pueraria lobata-derived exosome-like nanovesicles alleviate osteoporosis by enhacning autophagy

Alendronate Functionalized Bone-Targeting Pomolic Acid Liposomes Restore Bone Homeostasis for Osteoporosis Treatment

Injectable double-crosslinked bone cement with enhanced bone adhesion and improved osteoporotic pathophysiological microenvironment for osteoregeneration in osteoporosis

Bone targeting antioxidative nano-iron oxide for treating postmenopausal osteoporosis

Radial Extracorporeal Shock Wave Responsive Precise Nanoplatform for Effective Osteoporosis Sequential Treatment

Structure-based Development of an Osteoprotegerin-Like Glycopeptide That Blocks RANKL/RANK Interactions and Reduces Ovariectomy-Induced Bone Loss in Mice.

The nanoformula of zoledronic acid and calcium carbonate targets osteoclasts and reverses osteoporosis

Citric acid-modified pH-sensitive bone-targeted delivery of estrogen for the treatment of postmenopausal osteoporosis

Regulating Type H Vessel Formation and Bone Metabolism via Bone‐Targeting Oral Micro/Nano‐Hydrogel Microspheres to Prevent Bone Loss